FY26 Annual Report: Swings to Profit on $195M PRV Sale, Refocuses on Oncology
Sun Pharma Advanced Research Company Limited · SPARC · NSE ·
• <b>Financial Turnaround:</b> Reported a Profit After Tax of ₹1,55,320 lakhs for FY26, a significant swing from a loss of ₹34,251 lakhs in FY25. Basic EPS stands at ₹47.86 vs. (₹10.55) last year. • <b>Key Driver:</b> The profit was primarily driven by the one-time sale of a Prio…